Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02195024
Other study ID # PMUN-DB-001-MRIPM
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date July 2014
Est. completion date May 2017

Study information

Verified date January 2021
Source Paracelsus Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aim of this trial is to investigate feasibility of cardiac magnetic resonance imaging (cMRI) in patients with long term implanted coradial leads upgraded to an MRI conditional pacemaker system, to assess MR-image quality and to prove the safety of MRI in this specific population in the short term as well as during long term follow-up.


Description:

The trial is designed 1. To investigate the cardiac MRI related adverse event-free rate in patients with long term implanted coradial pacing leads (Fineline-II) after implantable pulse generator (IPG) exchange to a MRI conditional system (short term and long term): Safety. 2. To assess the technical performance of MRI conditional pacemaker systems with long term implanted coradial pacing leads, for cardiac MRI (short term and long term): Effectiveness pacemaker. 3. To assess the image quality (IQ) and the diagnostic value (DV) of the cardiac MRI scans in patients with implanted MRI conditional systems: Effectiveness cardiac MRI. 2) To evaluate the clinical incidence of MRI procedures in the population of long term implanted pacemaker patients (long term-follow up)


Recruitment information / eligibility

Status Terminated
Enrollment 23
Est. completion date May 2017
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Approved clinical indication for pectoral pacemaker exchange (e.g. elective replacement indication (ERI), end of service (EOS)) - Implantation of a CE certified / market released MRI conditional pacemaker (BSCI) consistent of - a single or dual chamber MRI conditional pacemaker (BSCI) or - Any comparable successor IPG (MRI conditional system, BSCI) compatible with - Implanted Fineline-II-leads (BSCI), MRI conditional - Leads electrically intact and with stable and normal function - The ascertained lead impedance is between 200 and 1500 Ohm. - All pacing capture thresholds (PCT) do not exceed 2.0 V @0.4 or 0.5 ms in pacemaker dependent patients - Adherence to the MRI conditions of use is given - Male or female 18 years or older - Understand the nature of the procedure - Give written informed consent - Able to complete all testing required by the clinical protocol - Ability to measure atrial and/or ventricular pacing threshold(s) at 0.4 or 0.5 ms - Patient body height greater or equal to 140 cm - Pectoral implanted device - Subjects who are able and willing to undergo elective cardiac magnetic resonance (MR) scanning without sedation (MRI-group) - Subjects who are geographically stable and available for follow-up at the study center for the length of the study Exclusion Criteria: - • Non MRI conditional leads implanted - Pacing threshold(s) (at 0.4 or 0.5 ms) and/or sensing amplitude(s) and/or impedance(s) are not measurable - Meet one or more of the contraindications for MRI including Psychiatric disorders, anxiety, claustrophobia Cardiac disorders that represent a contraindication to MRI - Cardiac surgery already scheduled in the next three months - Have other medical implants that may interact with MRI, e.g. abandoned implantable cardioverter defibrillator (ICD) leads or pacemaker leads other than MRI conditional, lead extensions, other active medical devices, non-MRI compatible devices, mechanical valve - Have other metallic artifacts/components in body that may interact with MRI - Subjects for whom a single dose of 1.0 milligram (mg) dexamethasone acetate may be contraindicated - Subjects who require a legally authorized representative to obtain consent - Subjects who are immediate candidates for an ICD - Subjects with medical conditions that preclude the testing required by the protocol or limit study participation - Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during this clinical study - Being pregnant - Have a life expectancy of less than three months - Subjects with exclusion criteria required by local law (e.g. age, breastfeeding)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
cardiac MRI group
• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans = six (6) weeks after device exchange

Locations

Country Name City State
Germany Klinikum Nürnberg Süd Nürnberg

Sponsors (2)

Lead Sponsor Collaborator
Dr. Dirk Bastian Boston Scientific Corporation

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other cMRI periprocedural observations / complaints Periprocedural observations / complaints during MRI
- Time interval: during MRI scanning, between pre- and post-MRI pacemaker interrogation
during cardiac MRI between pre- and post-MRI pacemaker interrogation
Other IPG dysfunction - Any IPG dysfunction (reset, reprogramming, over/undersensing, over-/underpacing, exit-block, loss of capture…), Battery changes after cMRI at any follow-up until the end of the trial (minimum 24 months)
Primary safety: cardiac MRI and pacing system related Serious Adverse Device Effects Primary outcome measure 1 (safety):
cMRI and pacing system related Serious Adverse Device Effect (SADE) free rate after 3 months.
Hypothesis: MRI and pacing system related Serious Adverse Device Effect (SADE) free-Rate is greater than 90% after 3 months.
3 months after cardiac MRI
Primary Effectiveness cardiac MRI: cMRI image quality (IQ) and diagnostic value (DV) Primary outcome measure 2 (Effectiveness cardiac MRI):
cMRI image quality (IQ) and diagnostic value (DV)
Hypothesis: cMRI IQ is "acceptable" and clinical use is not adversely affected in = 90% cMRI procedures
cMRI images done = six (6) weeks after device exchange
Secondary cMRI and pacing system related Adverse Device Effect The proportion of patients with a cMRI and pacing system related Adverse Device Effect (ADE) 1 and 3 months after cardiac MRI
Secondary Pacemaker performance under/after MRI (short and midterm) - Pacing capture threshold (PCT) rise (atrial and ventricular) The proportion of patients with an atrial or ventricular MRI induced pacing capture threshold rise larger than or equal to 100% voltage safety margin of the measured Pre-MRI pacing threshold at post-MRI interrogation, at 1-month and at 3 month follow- up
The proportion of patients with an atrial or ventricular MRI induced pacing threshold rise larger than or equal to 1.0 V @ 0.4 ms or 0.5 ms between pre-MRI and at post-MRI interrogation, 1 month and at 3-month follow-up
1 and 3 Months after cardiac MRI
Secondary Pacemaker performance under/after MRI (short and midterm): atrial or ventricular sensing amplitude - P and R-wave sensing attenuation:
o The proportion of patients with an atrial or ventricular amplitude decrease that exceed 50% between Pre-MRI evaluation and at post-MRI interrogation, at 1-month and at 3-month follow-up
between Pre-MRI evaluation and at post-MRI interrogation at 1-month and at 3-month follow-up after cMRI
Secondary - Long term pacing capture threshold rise (atrial and ventricular) The proportion of patients with an atrial or ventricular MRI induced pacing capture threshold rise larger than or equal to 100% voltage safety margin of the measured Pre-MRI pacing threshold between Pre-MRI interrogation and at 2 years follow- up
The proportion of patients with an atrial or ventricular MRI induced pacing capture threshold rise larger than or equal to 1.0 V @ 0.4 ms or 0.5 ms between Pre-MRI interrogation and at 2 years follow- up
Pre-MRI interrogation and at 2 years follow- up
Secondary - Long term P and R-wave sensing attenuation The proportion of patients with an atrial or ventricular amplitude decrease that exceed 50% between Pre-MRI interrogation and 2 years follow-up between Pre-MRI interrogation and 2 years follow-up
Secondary MRI procedures during long term-follow up Clinical incidence of MRI procedures during long term-follow up, device performance after repetitive MRI procedures during a minimum of 2 years follow-up
Secondary periprocedural cardiac troponin Cardiac high sensitive Troponin pre- and post-MRI as marker of thermal injury pre- and within 3 to 24 hours post-MRI
See also
  Status Clinical Trial Phase
Recruiting NCT03785171 - Predicative Value of Multimodal MRI in Moyamoya Disease
Not yet recruiting NCT03726788 - Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis Phase 2
Active, not recruiting NCT01956409 - Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Phase 4
Completed NCT01660841 - Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging Phase 3
Recruiting NCT03635619 - The Application of 3T MRI in Esophageal Cancer
Recruiting NCT03658343 - T2* MRI Analysis for Sarcoma N/A
Recruiting NCT04555642 - Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
Active, not recruiting NCT03441867 - Neuroimaging Biomarker for Seizures N/A
Recruiting NCT04850001 - Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
Not yet recruiting NCT05816213 - Point-of-care Low-field MRI in Acute Stroke
Active, not recruiting NCT05498623 - MR Fingerprinting for Diagnostic of Prostate Cancer
Recruiting NCT04257747 - Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI N/A
Recruiting NCT04996615 - Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
Recruiting NCT05889117 - Brain Stimulation for Concussion N/A
Completed NCT02540967 - Drug Use Investigation of Gadovist.
Completed NCT05103189 - 4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension N/A
Completed NCT02567318 - Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia? N/A
Recruiting NCT02834585 - Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT) N/A
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT01721785 - Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer N/A